Kornitzer Capital Management Inc. KS cut its holdings in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 0.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 212,749 shares of the company’s stock after selling 870 shares during the quarter. Kornitzer Capital Management Inc. KS owned about 0.56% of Deciphera Pharmaceuticals worth $4,797,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Deciphera Pharmaceuticals in the fourth quarter worth about $6,974,000. Dimensional Fund Advisors LP purchased a new position in shares of Deciphera Pharmaceuticals in the fourth quarter worth about $4,337,000. Marshall Wace North America L.P. raised its stake in shares of Deciphera Pharmaceuticals by 4,025.4% in the first quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after purchasing an additional 56,315 shares during the last quarter. CIBC Asset Management Inc purchased a new position in shares of Deciphera Pharmaceuticals in the first quarter worth about $958,000. Finally, Geode Capital Management LLC raised its stake in shares of Deciphera Pharmaceuticals by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock worth $3,503,000 after purchasing an additional 27,157 shares during the last quarter. Institutional investors own 59.10% of the company’s stock.
Several research analysts have recently issued reports on the company. ValuEngine cut Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 2nd. Piper Jaffray Companies raised their price objective on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Leerink Swann reissued a “positive” rating and issued a $29.00 price objective (up from $20.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday. Finally, Zacks Investment Research raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 price objective on the stock in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $47.90.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The business had revenue of $25.00 million for the quarter, compared to analyst estimates of $20.00 million. As a group, equities analysts expect that Deciphera Pharmaceuticals Inc will post -4.29 EPS for the current year.
In related news, CFO Thomas Patrick Kelly sold 2,100 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $25.20, for a total value of $52,920.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Daniel Lee Flynn sold 148,107 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $40.92, for a total value of $6,060,538.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 185,607 shares of company stock worth $7,536,409. Insiders own 7.02% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.